Plaque Psoriasis Market is projected to reach USD 41.27 billion by 2034

The global Plaque Psoriasis Market was valued at USD 21.84 billion in 2024 and is projected to reach USD 41.27 billion by 2034, expanding at a CAGR of 6.6% during the forecast period (2025-2034). Growth is driven by the strong adoption of biologics, rapid expansion of IL-17 and IL-23 inhibitor classes, rising psoriasis prevalence worldwide, and increasing use of targeted oral therapies for long-term disease control.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71345

Plaque psoriasis is the most common form of psoriasis, accounting for ~80-90% of all psoriasis cases. It is a chronic, immune-mediated inflammatory condition characterized by raised, scaly plaques affecting the scalp, elbows, knees, trunk, and other areas. The condition significantly impacts quality of life, leading to itching, pain, emotional distress, and social stigma.

Because plaque psoriasis is highly visible, persistent, and often associated with systemic inflammation, healthcare systems worldwide are focusing on earlier diagnosis and optimized long-term therapy management.

Key Market Highlights
• 2024 Market Size: USD 21.84 billion
• 2034 Forecast: USD 41.27 billion
• CAGR (2025-2034): 6.6%
• Largest Therapy Class: IL-17 & IL-23 biologics
• Fastest-Growing Segment: Oral targeted therapies (PDE4 & JAK inhibitors)

Epidemiology & Patient Pool Insights
1. Global Burden
Psoriasis affects ~125 million people globally, and plaque psoriasis constitutes the vast majority (80-90%).
2. Age Distribution
• Onset commonly occurs between ages 15-35, but the disease affects all age groups.
• Pediatric plaque psoriasis cases are increasing worldwide.
3. Severity Distribution
Among plaque psoriasis patients:
• ~30% have moderate disease
• ~20% have severe disease
These groups are primary users of biologics and systemic treatments.
4. Comorbidities
Patients often have higher risk of:
• Psoriatic arthritis
• Metabolic syndrome
• Hypertension
• Type 2 diabetes
• Depression/anxiety
• Cardiovascular diseases
This contributes to demand for long-term systemic therapy.

Market Growth Drivers
1. High Adoption of Biologic Therapies
Biologics targeting:
• IL-17
• IL-23
• IL-12/23
• TNF-α
offer superior skin clearance and safety, driving rapid global uptake.
2. Rise of Targeted Oral Therapies
PDE4 and JAK inhibitors address unmet needs for:
• Patients averse to injections
• Mild-to-moderate patients escalating therapy
• Combination therapy strategies
3. Improved Clinical Guidelines
Dermatology associations recommend earlier systemic therapy for plaque psoriasis to prevent long-term inflammation and comorbidities.
4. Strong Pipeline Activity
New IL-23 inhibitors, oral immunomodulators, and regenerative dermatology products are entering late-stage development.
5. Digital Psoriasis Management
AI-based PASI scoring and teledermatology increase diagnosis and treatment adherence.

Market Restraints
• High cost of biologics and advanced systemic therapies
• Limited access to dermatologists in developing regions
• Potential long-term safety concerns
• Insurance restrictions (step therapy, prior authorization)
• Underdiagnosis and stigma delaying treatment

Market Opportunities
1. Expansion of IL-23 Inhibitors
Longer dosing intervals and superior clearance profiles drive strong future growth.
2. Growing Use of JAK Inhibitors
Highly effective for plaques and scalp involvement, offering convenient oral dosing.
3. Biosimilars
Lower cost biologics expand access, especially in emerging markets.
4. Personalized Dermatology
Biomarker-driven therapy selection will become more common over the next decade.
5. Innovative Topical Therapies
New steroid-free and combination formulations for early-stage plaque psoriasis.

Segmentation Overview
By Treatment Type
• Topical therapies (steroids, vitamin D analogs, combination products)
• Phototherapy
• Systemic therapies
• Biologics (IL-17, IL-23, TNF inhibitors)
• Oral targeted agents (PDE4, JAK inhibitors)

By Route of Administration
• Topical
• Oral
• Injectable

By Patient Group
• Adults
• Adolescents
• Pediatric patients

By End User
• Hospitals
• Dermatology clinics
• Specialty infusion centers
• Retail & online pharmacies

Explore Full Report here: https://exactitudeconsultancy.com/reports/71345/plaque-psoriasis-market

Regional Insights
North America - Largest Market
High biologic penetration, widespread screening, and strong payer coverage.
Europe - Strong Clinical Pathways
Structured national guidelines ensure consistent use of biologics and advanced therapies.
Asia Pacific - Fastest Growing Region
Increasing prevalence, expanding middle class, and improved dermatology access.
Latin America - Steady Growth
Growing awareness and improved access to systemic therapies.
Middle East & Africa - Emerging Market
Improved healthcare infrastructure supports steady therapeutic adoption.

Competitive Landscape
Major companies active in plaque psoriasis therapies:
• Novartis
• Eli Lilly
• AbbVie
• Johnson & Johnson (Janssen)
• Amgen
• UCB Pharma
• Bristol Myers Squibb
• Pfizer
• Sun Pharmaceutical
• LEO Pharma
These companies focus on advanced biologics, JAK inhibitors, oral immunomodulators, and novel topicals.

Recent Market Developments
• Long-term data from IL-17/IL-23 inhibitors demonstrating sustained PASI90/PASI100 clearance
• JAK inhibitors gaining traction for moderate-to-severe plaque psoriasis
• Approval of pediatric-friendly formulations and dosing regimens
• AI-based psoriasis monitoring tools expanding in clinics
• Launch of new biosimilars increasing affordability

Future Outlook (2025-2034)
The Plaque Psoriasis Market will continue to expand steadily as:
• Biologics dominate treatment algorithms
• JAK inhibitors reshape oral therapy demand
• Precision dermatology accelerates personalized treatment
• Digital tools improve disease monitoring
• Biosimilars increase therapy accessibility worldwide
By 2034, the market is set to reach USD 41.27 billion, reflecting sustained long-term demand for advanced psoriasis therapies.

This report is also available in the following languages : Japanese (尋常性乾癬市場), Korean (플라크 건선 시장), Chinese (斑块状银屑病市场), French (Marché du psoriasis en plaques), German (Markt für Plaque-Psoriasis), and Italian (Mercato della psoriasi a placche), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71345

Our More Reports:

Chronic Plaque Psoriasis Market
https://exactitudeconsultancy.com/reports/71377/chronic-plaque-psoriasis-market

Moderate to Severe Plaque Psoriasis ( ONLY CANADA DATA) Market
https://exactitudeconsultancy.com/reports/71425/moderate-to-severe-plaque-psoriasis-only-canada-data-market

Plaque Psoriasis (Psoriasis Vulgaris) Clinical Market
https://exactitudeconsultancy.com/reports/73631/plaque-psoriasis-psoriasis-vulgaris-clinical-market

Plaque Psoriasis in 68 Market
https://exactitudeconsultancy.com/reports/73643/plaque-psoriasis-in-68-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.